What's hot

View all perspectives
What's Hot
Sleep asleep

Sleep Quality & Psoriatic Arthritis

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.

Read more →

Ultrasound in PsA

Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

Watch video →

Tapering TNFi in nonradiographic AxSpA

Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.

Watch video →

Sunday (Day 2): ACR 22 Daily Recap

ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.

Watch video →

Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression

Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)

Watch video →

Deucravacitinib in PsA

Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

Watch video →

Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial

Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Watch video →

Best of ACR Day Two in PSA

Watch video →

PET CT Imaging to Define Risk of Progression from PSO to PsA

Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.

Watch video →

ACR22 Daily Recap: Saturday Recap

Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate. 

Watch video →
      RT @drdavidliew: We know depression, anxiety are issues for many RA pts. Are we making the diagnosis more?

      Olmsted Coun

      David Liew drdavidliew

      3 years 1 month ago
      We know depression, anxiety are issues for many RA pts. Are we making the diagnosis more? Olmsted County data: depression similar over time anxiety 3x more common in 2005-2014 vs 1985-1994 (adj age/sex +/- others) How do we address this? ABST0886 @MayoClinic #ACR22 @RheumNow https://t.co/tzMEE24FZo
      RT @RichardPAConway: Molina et al. Dupilumab (IL4/IL13 mab) in refractory EGPA. Complete response 49%, partial 43%. But

      Richard Conway RichardPAConway

      3 years 1 month ago
      Molina et al. Dupilumab (IL4/IL13 mab) in refractory EGPA. Complete response 49%, partial 43%. But flares in 27%. Dupilumab-induced eosinophilia in 57%. @RheumNow #ACR22 Abstr#1074 https://t.co/cziyHNPN3j https://t.co/h7gWAShQeL
      RT @RichardPAConway: Zuo @jasonsknight et al. Dallas Heart Study. aPL and incident CV events. IgA isotypes of aCLand aβ

      Richard Conway RichardPAConway

      3 years 1 month ago
      Zuo @jasonsknight et al. Dallas Heart Study. aPL and incident CV events. IgA isotypes of aCLand aβ2GPI were independently associated with future ASCVD events. @rheumnow #ACR22 Abstr#0681 https://t.co/C7O4rnFZCG https://t.co/1H7uiPUwuv
      RT @uptoTate: Abs 0674 finds that HIT is rare among hospitalized APS and SLE patients with aPL and that anti-PF4 antibod

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Abs 0674 finds that HIT is rare among hospitalized APS and SLE patients with aPL and that anti-PF4 antibodies are often inappropriately tested in this population. #ACR22 @RheumNow https://t.co/hFZzpuEkDG https://t.co/hyUYVZLUM4
      RT @DrTrishHarkins: 🔥 VEXAS + the 🫁 🔥

      🔑 Points ~

      🫁 involvement common

      👉cough + dyspnea

      🌬PFT

      Patricia Harkins DrTrishHarkins

      3 years 1 month ago
      🔥 VEXAS + the 🫁 🔥 🔑 Points ~ 🫁 involvement common 👉cough + dyspnea 🌬PFTS often normal 🩻 CXR useful but HRCT superior 🩻ground glass opacity commonest finding 💊 good response GC 🔥ignite session🔥 #ACR22 Abst# 1569 @RheumNow
      RT @uptoTate: Abs 0345 finds association between cumulated HCQ and development of cardiac abnormalities. We need further

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Abs 0345 finds association between cumulated HCQ and development of cardiac abnormalities. We need further data to determine clinical association. #ACR22 @RheumNow https://t.co/WmixbFIlfd https://t.co/2Ejwkeu1Az
      RT @uptoTate: In the absence of other high risk factor for thrombosis, Thrombocytopenia (ITP) could be an independent an

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      In the absence of other high risk factor for thrombosis, Thrombocytopenia (ITP) could be an independent and long-lasting clinical phenotype for aPLs carriers. Abs 0672 #ACR22 @RheumNow https://t.co/LmlruGqkEJ https://t.co/MaIHS0QWN0
      RT @drdavidliew: Sometimes we guess how RA pts will be, before they come in.

      machine learning to predict RA dx activity

      David Liew drdavidliew

      3 years 1 month ago
      Sometimes we guess how RA pts will be, before they come in. machine learning to predict RA dx activity: RISE registry (n=39,155) inputs: prev CDAI, demo, smoking/obesity, SES v good performance Past performance does predict future outcomes, sometimes! ABST0905 #ACR22 @RheumNow https://t.co/Ir1YG1cqlD
      RT @RichardPAConway: Kajiyama et al. JAKi counteract cellular toxicity of HCQ in vitro. Could they prevent HCQ-retinopat

      Richard Conway RichardPAConway

      3 years 1 month ago
      Kajiyama et al. JAKi counteract cellular toxicity of HCQ in vitro. Could they prevent HCQ-retinopathy? @rheumnow #ACR22 Abstr#0653 https://t.co/c0a4OYCzw5 https://t.co/X7pFM7j1R4
      RheumNow’s expanded coverage of the #ACR22 meeting is sponsored in part by Bristol-Myers Squibb. All content chosen b

      Dr. John Cush RheumNow

      3 years 1 month ago
      RheumNow’s expanded coverage of the #ACR22 meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty
      RT @RichardPAConway: Park et al. Risk-benefit of PJP propylaxis in rituximab treated patients. NNH 86 . NNT - all RTX 14

      Richard Conway RichardPAConway

      3 years 1 month ago
      Park et al. Risk-benefit of PJP propylaxis in rituximab treated patients. NNH 86 . NNT - all RTX 146, RTX+high dose steroid 21. This mirrors my practice @RheumNow #ACR22 Abstr#0720 https://t.co/JPtPCqah9R https://t.co/bonRzWFbVw
      RT @RichardPAConway: Kaneko et al. Tocilizumab leads to significantly lower steroid doses in Adult onset Stills Disease

      Richard Conway RichardPAConway

      3 years 1 month ago
      Kaneko et al. Tocilizumab leads to significantly lower steroid doses in Adult onset Stills Disease @RheumNow #ACR22 Abstr#0826 https://t.co/jc1S6sdfkm https://t.co/z0cHB4wYu6
      RT @doctorRBC: What neonatal factors could affect development into axSpA? Turns out antibiotic exposure (6.2x more likel

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      What neonatal factors could affect development into axSpA? Turns out antibiotic exposure (6.2x more likely). Mode of delivery, early diet (milk vs. formula), maternal smoking (!!) did not show association. @RheumNow #ACR22 Abs#0868 #ACRBest https://t.co/roCAj5YsCt
      RT @uptoTate: In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe in

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe infection compared to MTX, AZA, MMF. Abs 0349 #ACR22 @RheumNow https://t.co/0EBpCMPOqF https://t.co/vdxKVJSaZA
      RT @RichardPAConway: Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stab

      Richard Conway RichardPAConway

      3 years 1 month ago
      Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stabalised renal function (vs decline in PBO), less steroid increase (14% vs 36%), UPCR declined (vs increase in PBO) @RheumNow #ACR22 Abstr#1001 https://t.co/FRWcTAgCrn https://t.co/Amkg84OX2x

      Podcasts

      • ACR2022 - Day 4 00:14:40
      • Monday ACR 2022 Daily Recap 00:37:20
      • ACR2022 - Day 3.3 00:34:23

      Catch up on Conference Podcasts

      ×